Thus, keeping ALT activity continuously low (≦30 IU/l ), demarcating the moderately at risk ALT group (30–50 IU/L) and initiating IFN re-treatment and other supplementary treatments, even in elderly, non-responder patients, may be helpful in prevention or delay of HCC occurrence. The gene discussed is GPT; the disease is hepatocellular carcinoma.